Quantcast

Candian Company Fights U.S. Flu

Get the WebProNews Newsletter:
[ Business]

The Food and Drug Administration approved ID Biomedical of Canada to begin their Fluviral flu vaccine for the U.S.

The company has intentions of beginning the trial enrollment process this month. They also have intentions of operating in the United States if approved by the FDA.

ID Biomedical stated, “Once we have a full picture, we can determine whether accelerated approval is feasible for this year.”

According to Reuters,

“Medicare will test the idea of paying for antiviral drugs for some patients who catch influenza, the U.S. government’s health insurance plan for the elderly said on Friday.

The so-called demonstration project will allow patients who are not enrolled for drug coverage to get help in paying for four drugs that can treat influenza — Roche AG’s Tamiflu, also known as oseltamivir; zanamivir, sold by GlaxoSmithKline under the brand name Relenza; and the older drugs amantadine and rimantadine.”

Dr. Mark McClellan, administrator of the Centers for Medicare & Medicaid Services says, “There are prescription drugs that have been proven to prevent the flu and its serious complications, and Medicare is taking steps to make these drugs more affordable.”

WebProNews | Breaking eBusiness News
Your source for investigative ebusiness reporting and breaking news.

Candian Company Fights U.S. Flu
Comments Off
Top Rated White Papers and Resources

Comments are closed.